BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22685558)

  • 1. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
    Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
    PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
    Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression.
    Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
    Br J Dermatol; 2013 Sep; 169(3):618-28. PubMed ID: 23662813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
    Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
    J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
    Wild PJ; Meyer S; Bataille F; Woenckhaus M; Ameres M; Vogt T; Landthaler M; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    Arch Dermatol; 2006 Apr; 142(4):471-6. PubMed ID: 16618867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.
    Pacifico MD; Grover R; Richman PI; Daley FM; Buffa F; Wilson GD
    Plast Reconstr Surg; 2005 Feb; 115(2):367-75. PubMed ID: 15692338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
    Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
    J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
    Guo H; Cheng Y; Martinka M; McElwee K
    Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
    Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
    J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying High-Risk Tumors within AJCC Stage IB-III Melanomas Using a Seven-Marker Immunohistochemical Signature.
    Reschke R; Gussek P; Ziemer M
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 13. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. nm23 as a prognostic marker in primary cutaneous melanoma: evaluation using tissue microarray in a patient group with long-term follow-up.
    Pacifico MD; Grover R; Richman PI; Buffa F; Daley FM; Wilson GD
    Melanoma Res; 2005 Oct; 15(5):435-40. PubMed ID: 16179871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
    Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G
    Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray.
    Pacifico MD; Grover R; Richman PI; Daley FM; Buffa F; Wilson GD
    Int J Cancer; 2006 Mar; 118(6):1460-4. PubMed ID: 16187282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.
    Bose P; Klimowicz AC; Kornaga E; Petrillo SK; Matthews TW; Chandarana S; Magliocco AM; Brockton NT; Dort JC
    BMC Cancer; 2012 Aug; 12():332. PubMed ID: 22852863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
    Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
    J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.